GTC
REGN icon

Ghost Tree Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Ghost Tree Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-7,500
Closed -$2.12M – 80
2014
Q2 		$2.12M Buy
+7,500
New +$2.22M 1.49% 26

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Ghost Tree Capital's REGN Position: Q3 2014 in Review

Ghost Tree Capital sold out of Regeneron Pharmaceuticals (REGN) in Q3 2014, closing a stake of 7,500 shares — an estimated $2.12M sold.

Ghost Tree Capital first reported a position in REGN in Q2 2014 and held it in 1 quarter. The position peaked at $2.12M in Q2 2014. 473 funds tracked by Wall St. Rank hold REGN as of Q3 2014.

  • Ghost Tree Capital reported no remaining Regeneron Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Ghost Tree Capital sold 7,500 Regeneron Pharmaceuticals shares in Q3 2014, an estimated $2.12M.
  • Ghost Tree Capital first reported a position in Regeneron Pharmaceuticals in Q2 2014 and held it in 1 quarter.
  • Ghost Tree Capital's Regeneron Pharmaceuticals position peaked at $2.12M in Q2 2014.
  • 473 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2014.

Based on Ghost Tree Capital's 13F filing for Q3 2014, filed 14 Nov 2014.